Home・Список акций・AnaptysBio Inc

AnaptysBio Inc

Закрыт

СекторЗдравоохранение

56.23 3.14

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

55.79

Макс.

56.6

Ключевые показатели
By Trading Economics
Доход	-102M -53M
Продажи	-83M 26M
Прибыль на акцию	-1.843
Рентабельность продаж	-206.934
Сотрудники	104
EBITDA	-99M -31M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+42.5% upside

Дивиденды
By Acuity
Следующий отчет о доходах	11 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-388M 1.6B
Предыдущая цена открытия	53.09
Предыдущая цена закрытия	56.23

Новостные настроения

By Acuity

50%

128 / 340 Рейтинг в Healthcare

AnaptysBio Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 19:26 UTC

AnaptysBio Inc. shares are trading higher today, continuing a trend since Thursday's close, despite notable volatility during the session.

5 авг. 2026 г., 19:36 UTC

AnaptysBio Inc. shares are lower in Wednesday's session, having declined from earlier highs amid routine market fluctuations and trading near the lower end of its recent range.

3 авг. 2026 г., 20:06 UTC

AnaptysBio Inc shares are higher today, recovering from earlier losses amid a broader market rally in the S&P 500 and Nasdaq 100 indices.

31 июл. 2026 г., 20:06 UTC

AnaptysBio Inc shares are lower, reflecting broader market weakness amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 июл. 2026 г., 23:36 UTC

AnaptysBio Inc. shares declined after-market, reflecting ongoing weakness amid broader market volatility and the Federal Reserve's interest rate decisions.

29 июл. 2026 г., 19:56 UTC

Macro Event

AnaptysBio Inc shares are higher, recovering from an earlier dip, amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

28 июл. 2026 г., 23:16 UTC

AnaptysBio Inc shares are higher in after-market trading, recovering from earlier lows. No specific news was identified to explain the movement.

24 июл. 2026 г., 19:16 UTC

AnaptysBio Inc shares are lower today, reflecting a decline since Thursday. Broader market sentiment is affected by recent volatility in oil prices.

23 июл. 2026 г., 09:16 UTC

AnaptysBio Inc is trading lower in pre-market hours amid broader market pressures from disappointing earnings reports and rising geopolitical tensions.

22 июл. 2026 г., 22:16 UTC

AnaptysBio Inc shares are higher in after-market hours, trading above Wednesday's close amid broader market concerns over rising crude oil prices and U.S.-Iran tensions.

21 июл. 2026 г., 20:12 UTC

AnaptysBio Inc. shares are lower in after-market trading, continuing a downward trend and positioning the stock below its 20-day moving average.

20 июл. 2026 г., 23:01 UTC

AnaptysBio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

AnaptysBio Inc Прогноз

Целевая цена

By TipRanks

42.5% рост

Прогноз на 12 месяцев

Средняя 80.67 USD 42.5%

Максимум 95 USD

Минимум 70 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для AnaptysBio Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

Покупка

Удержание

Продажа

Основано на мнении 7 аналитиков, присваивавших рейтинги акциям AnaptysBio Inc – Данные за последние 3 месяца.

Настроения

By Acuity

128 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.